Form 4: Lucid Diagnostics Director Stanley Lapidus Acquires 112,800 Shares of Restricted Stock

Director Stanley Lapidus acquired 112,800 shares of Lucid Diagnostics Inc. restricted stock on February 20, 2025, under the company's 2018 Equity Plan.

Summary

• On February 20, 2025, Stanley Lapidus, a director of Lucid Diagnostics Inc., acquired 112,800 shares of common stock.
• The acquisition was a grant of restricted stock under the Issuer's 2018 Equity Plan.
• The restricted stock was acquired at a price of $0 per share.
• The shares vest on May 20, 2028, and are subject to forfeiture if the required service period is not completed.
• Following the transaction, Lapidus directly owns 214,392 shares of Lucid Diagnostics Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of restricted stock is a common practice and indicates a commitment to aligning management interests with shareholders. There are no overtly negative aspects presented in the filing.

Positives

• The acquisition of restricted stock aligns the director's interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could impact the director's motivation if circumstances change.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of a director's stock ownership and is typical for publicly traded companies. It reflects part of the company's compensation strategy to align management's interests with shareholders.

Stakeholder Impact

• The granting of restricted stock can positively impact shareholders by aligning the director's interests with the company's long-term performance.

Key Dates

Keywords

Lucid Diagnostics, Stanley Lapidus, restricted stock, director, equity plan, beneficial ownership, Form 4